FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 182.19

Change

+3.16 (+1.77)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.41 (+0.96%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.20%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+0.80 (+0.73%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.02 (+1.07%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.78 (+3.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.67 (+2.03%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.37 (+0.36%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.59 (+1.93%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.21 (+1.95%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.79 (+3.41%)

USD 6.89M

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 98.47 % 0.00 %

+0.40 (+1.23%)

CAD 1.83M
FHM:CA 0.00 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.61% 86% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.61% 86% B+ 88% B+
Trailing 12 Months  
Capital Gain 22.79% 100% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.79% 100% F 75% C
Trailing 5 Years  
Capital Gain 21.53% 38% F 60% D-
Dividend Return 1.48% 37% F 4% F
Total Return 23.01% 38% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 38% F 38% F
Dividend Return 1.53% 38% F 29% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.13% 90% A- 74% C
Risk Adjusted Return 12.63% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.